[Therapeutic use of metadoxine in chronic alcoholism. Double blind study of patients in a department of general medicine]

Clin Ter. 1993 Mar;142(3):243-50.
[Article in Italian]


Sixty patients, recognized as chronic alcoholics on the grounds of the case history and with a score above 11 of the Munich Alcoholism Test (MALT) have been treated with metadoxine or placebo for thirty days according to a double blind randomized design. In the group treated with active drug there has been a significant reduction higher than in the controls of the scores relating to the abstinence symptomatology, in particular regarding the neuropsychic residual symptomatology (anxiety, depression, insomnia) after the first week of treatment, a reduced requirement of benzodiazepines and/or neuroleptics, and a significant decrement higher than in the controls of the score of MALT at the end of treatment. Furthermore, metadoxine seems to make easy the maintenance of abstinence, at least at short term.

Publication types

  • Clinical Trial
  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • Alcoholic Intoxication / drug therapy
  • Alcoholism / drug therapy*
  • Double-Blind Method
  • Drug Combinations
  • Drug Evaluation
  • Female
  • Hospital Departments
  • Humans
  • Italy
  • Male
  • Middle Aged
  • Pyridoxine / therapeutic use*
  • Pyrrolidonecarboxylic Acid / therapeutic use*
  • Substance Withdrawal Syndrome / drug therapy


  • Drug Combinations
  • metadoxine
  • Pyridoxine
  • Pyrrolidonecarboxylic Acid